protein degradation

Revised Blueprint-VantAI deal turns focus to molecular glues

Blueprint Medicines is revising a pact with VantAI again, this time adding a focus for historically “undruggable” targets and prioritizing new target-effector pairs that could be used to develop molecular glue therapeutics.

Gabrielle Masson May 20, 2025 10:32am

C4T halts BRAF degrader work to save cash for cemsidomide

May 7, 2025 7:00am

Graphic of two hands shaking under a red and purple light

Sanofi pays Nurix $15M upfront for autoimmune degrader

Apr 2, 2025 8:10am

Cartoon of magnet pulling coins toward it

Eli Lilly feels Magnet's pull with hefty molecular glue deal

Feb 28, 2025 6:30am

AbbVie crafts $1.6B deal with molecular glue biotech Neomorph

Jan 23, 2025 9:58am

pivot change turnaround direction walk away

Kymera pivots to immunology, seeks partners for cancer assets

Nov 1, 2024 11:46am